ClinicalTrials.gg
Enrolling by invitationNCT06507449Updated Nov 12, 2026

The Influence of Modifying Highly Calcified Coronary Lesions on Coronary Microcirculation

An interventional study of Lithotripsy and Orbital atherectomy in Coronary Artery Calcification, Ischemic Heart Disease and Non-ST-Segment Elevation Myocardial Infarction (NSTEMI), sponsored by Medical University of Silesia. Enrolling by invitation at 1 site in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Medical University of Silesia · Not applicable, Interventional, and Treatment

How we know

Updated Nov 12, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 35 studies in Myocardial Ischemia with a site in Poland — 4 open to participants now, 9 under way, 1 of them phase 3. Myocardial Ischemia · Poland.

Planned enrollment
27th of 27
30 · median 697
Started
2026
with 1 other
No phase
11 of 35
4 open now
Registered
32nd of 35
by date

Among the 35 studies in Myocardial Ischemia with a site in Poland, this one is the 27th largest by planned enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2026, is one of 11 with no phase, and was the 32nd registered.

Myocardial Ischemia

1,123 studies on the registry are indexed under Myocardial Ischemia; 177 are open to participants now.

Browse Myocardial Ischemia studies →

Open to participants now

4 of the 35 studies in Myocardial Ischemia with a site in Poland are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 135 Myocardial Ischemia studies recruiting now, 92 (68%) set no upper age limit and 6 (4%) stop at 75 or younger; 14 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Myocardial Ischemia with a site in Poland, or all of them as a file.
02

Study summary

This is a prospective, single-center, three-arm study to evaluate the impact of severely calcified coronary lesions treatment on microvascular circulation. We will enroll 30 conveniently sampled subjects assigned to one of three therapeutical methods lithotripsy, super-high pressure balloon, and orbital atherectomy prior to implantation of drug-eluting stents (DES).

Read the detailed description

This prospective, non-randomized, single-center study includes subjects who meet all of the inclusion and none of the exclusion criteria and sign the ICF. 30 patients with severe coronary stenosis will be enrolled. The severity will be assessed by Optical Coherence Tomography (OCT) based on the degree of calcification in the coronary lesion as defined by this protocol. Subjects will be assigned to one of three arms (lithotripsy, super-high pressure balloon or orbital atherectomy) followed by an implantation of drug-eluting stents (DES). The aposition and expansion of DES will be evaluated using OCT . Patients will be followed through discharge, 30 days and 12 months.

03

Conditions studied

  • Coronary Artery Calcification
  • Ischemic Heart Disease
  • Non-ST-Segment Elevation Myocardial Infarction (NSTEMI)
  • Coronary Artery Disease
  • Angina, Unstable
  • Tomography, Optical Coherence

Keywords

  • Percutaneous coronary intervention
  • Microcirculation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with native coronary artery disease (including stable or unstable angina and NSTEMI) suitable for PCI.
  • The lesion must be crossable with the study guide wire.
  • The target vessel reference diameter must be ≥ 2.5mm and ≤ 4.0 mm.
  • The target lesion must have evidence of severe calcium deposit at the lesion site based on the protocol criterion.
  • Subject or legally authorized representative, signs a written form to participate in the study, prior to any study-mandated procedures.
  • Male or female, age above or equal to 18 years at the time of signing informed consent.

Further inclusion criteria may apply

Exclusion criteria

Exclusion Criteria:

  • Inability to understand the study or a history of non-compliance with medical advice.
  • Unwilling or unable to sign the Form (ICF).
  • History of any cognitive or mental health status that would interfere with trial participation.
  • Male or female, age under 18 years at the time of signing informed consent.
  • Female subjects who are pregnant or planning to become pregnant within the study period.
  • Subject has a known sensitivity to contrast media, which cannot be adequately pre-medicated.
  • Subject has evidence of an active infection on the day of the procedure requiring oral or intravenous antibiotics.
  • Limited long term prognosis due to other conditions.
  • Subjects in cardiogenic shock or with decompensated heart failure ( class IV).
  • Subject diagnosed with chronic kidney disease stage 4 or greater ( \<30).
  • Most recent ≤ 20%.
  • Subject is an acceptable candidate for coronary artery bypass surgery.
  • The target vessel reference diameter is under 2.0 mm.
  • Target lesion is located in or supplied by an arterial or venous bypass graft.
  • The target vessel has angiographically visible or suspected thrombus.
  • The target lesion is in an in-stent restenosis.
  • Subject has received a heart transplant.
  • Subject has major valve disease and underwent intervention within 30 days prior to randomization.

Further exclusion criteria may apply

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    High-pressure non-compliant balloon

    The SIS Medical OPN NC® super high-pressure coronary balloon will be used for balloon angioplasty vessel preparation prior to implantation of a drug-eluting stent.

    Device: High-pressure non-compliant balloon · Device: Optical coherence tomography · Device: Coroventis Coroflow Cardiovascular System and PressureWire™ X Guidewire

  • Experimental
    Orbital atherectomy

    The Diamondback 360® Coronary Orbital Atherectomy System (OAS) will be used for orbital atherectomy (OA) vessel preparation prior to implantation of a drug-eluting stent.

    Device: Orbital atherectomy · Device: Optical coherence tomography · Device: Coroventis Coroflow Cardiovascular System and PressureWire™ X Guidewire

  • Experimental
    Lithotripsy

    The Shockwave® Medical system will be used for intravascular lithotripsy (IVL) vessel preparation prior to implantation of a drug-eluting stent.

    Device: Lithotripsy · Device: Optical coherence tomography · Device: Coroventis Coroflow Cardiovascular System and PressureWire™ X Guidewire

Interventions

  • DeviceLithotripsy

    Calcified lesion preparation using lithotripsy before implantation of a drug-eluting stent

  • DeviceOrbital atherectomy

    Calcified lesion preparation using orbital atherectomy before implantation of a drug-eluting stent

  • DeviceHigh-pressure non-compliant balloon

    Calcified lesion preparation using high-pressure non-compliant balloon before implantation of a drug-eluting stent

  • DeviceOptical coherence tomography

    Optical coherence tomography assessment of coronary arteries.

  • DeviceCoroventis Coroflow Cardiovascular System and PressureWire™ X Guidewire

    A coronary thermodilution system used for evaluate differences between the impact of calcified lesion preparation methods on coronary microvascular function.

06

What researchers measure

Primary outcomes

  1. Coronary Flow Reserve (CFR)

    Determination of a difference between Coronary Flow Reserve (CFR) at the beginning and at the end of the procedure using CoroFlow™ Cardiovascular System.

    Time frame: Intraprocedural

  2. Index of Microcirculatory Resistance (IMR)

    Determination of a difference between Index of Microcirculatory Resistance (IMR) at the beginning and at the end of the procedure using CoroFlow™ Cardiovascular System.

    Time frame: Intraprocedural

Secondary outcomes

  1. Stent expansion

    Stent expansion (%) evaluated by optical coherence tomography.

    Time frame: Intraprocedural

  2. Acceptable stent expansion

    Acceptable stent expansion (cut-off value defined as \>80%) evaluated by optical coherence tomography.

    Time frame: Intraprocedural

  3. Optimal stent expansion

    Optimal stent expansion (cut-off value defined as \>90%) evaluated by optical coherence tomography.

    Time frame: Intraprocedural

  4. Minimal lumen diameter (MLD) difference

    Determination of a difference between quantitative OCT measured minimal lumen diameter (MLD) at the beginning and at the end of the procedure.

    Time frame: Intraprocedural

  5. Procedural Success

    Procedural success - defined as successful stent delivery and angiographic in-vessel residual stenosis \<30%, and with the absence of any of the following: stent loss, coronary artery dissection, coronary artery perforation, PCI no reflow phenomenon or MACCE (defined as a composite of cardiovascular death, myocardial infarction at the targeted vessel, targeted coronary vessel revascularization (PCI or CABG), TIA or stroke).

    Time frame: Up to 3 years

  6. Strategy Success

    Strategy success - defined as procedural success without crossover to alternative treatment.

    Time frame: Intraprocedural

Other outcomes

  1. The proportion of subjects that experience Major Adverse Cardiovascular and Cerebrovascular Events (MACCE)

    30-day and 1 year MACCE defined as a composite of cardiovascular death, myocardial infarction at the targeted vessel, targeted coronary vessel revascularization (PCI or CABG), TIA or stroke.

    Time frame: Up to 3 years

  2. The proportion of subjects that experience Target Vessel Revascularization (TVR)

    30-day and 1 year Target Vessel Revascularization (TVR) - defined as any repeat revascularization at the target vessel (inclusive of the target lesion) and target vessel collaterals after the completion of the procedure.

    Time frame: Up to 3 years

  3. The proportion of subjects that experience Target Lesion Revascularization (TLR)

    30-day and 1 year Target Lesion Revascularization (TLR) - defined as repeat intervention PCI or surgery within the index procedure stent or 5mm proximal or distal to the stent.

    Time frame: Up to 3 years

  4. Myocardial infarction (MI) rate at 30-day and 1 year

    The proportion of subjects that experience a Myocardial Infarction (MI) at 30-day and 1 year.

    Time frame: Up to 3 years

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2026 (actual). Primary completion is estimated for Aug 2027, 9 months after the start.

Of 155 non-industry interventional studies with no phase under Myocardial Ischemia, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 56. This study's planned 9 months is below that.

Counting every sponsor, half of 192 studies reached it within 34 months; a quarter within 15 and three quarters within 58.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: start Mar 2024 → Nov 2026, primary completion Jun 2026 → Aug 2027 and completion Dec 2026 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 12, 2024
First posted
Jul 18, 2024
StartActual
Nov 10, 2026was Mar 2024
Primary completionEst.
Aug 2027was Jun 2026
CompletionEst.
Dec 2027was Dec 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Mar 7, 2024→Nov 10, 2026
Nov 12, 2026
Primary completion
Jun 2026→Aug 2027
Nov 12, 2026
Study completion
Dec 2026→Dec 2027
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Start date Mar 7, 2024→Nov 10, 2026
    Primary completion Jun 2026→Aug 2027
    Study completion Dec 2026→Dec 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06507449
Collaborators
Polish Cardiac Society
Responsible party
Sponsor
First posted
Jul 18, 2024
Start date
Nov 10, 2026
Primary completion
Aug 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

Paweł Gąsior, MD, PhD
principal investigator · Division of Cardiology and Structural Heart Diseases, Medical University of Silesia

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion